U.S. stocks are down in morning trading Friday, pulling the market back from all-time highs, as the Trump administration ...

In the highly regulated world of life sciences, quality isn’t a box to check—it’s a business imperative. For global en ...

The stock's fall snapped a two-day winning streak.

What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in ...

Stocks are mostly lower on Wall Street, pulling the S&P 500 and the Nasdaq composite below the records they set a day earlier ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its innovative HIV treatments, is navigating a complex landscape of opportunities and challenges as it seeks to ...

Gilead Sciences' profit was reduced by unusual items worth US$3.3b in the last twelve months, and this helped it produce high cash conversion, as reflected by its unusual items.